• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓活检在 MPN 中的定量解读——在分子时代有何意义?

Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?

机构信息

Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

出版信息

Br J Haematol. 2023 Nov;203(4):523-535. doi: 10.1111/bjh.19154. Epub 2023 Oct 19.

DOI:10.1111/bjh.19154
PMID:37858962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10952168/
Abstract

The diagnosis of myeloproliferative neoplasms (MPN) requires the integration of clinical, morphological, genetic and immunophenotypic findings. Recently, there has been a transformation in our understanding of the cellular and molecular mechanisms underlying disease initiation and progression in MPN. This has been accompanied by the widespread application of high-resolution quantitative molecular techniques. By contrast, microscopic interpretation of bone marrow biopsies by haematologists/haematopathologists remains subjective and qualitative. However, advances in tissue image analysis and artificial intelligence (AI) promise to transform haematopathology. Pioneering studies in bone marrow image analysis offer to refine our understanding of the boundaries between reactive samples and MPN subtypes and better capture the morphological correlates of high-risk disease. They also demonstrate potential to improve the evaluation of current and novel therapeutics for MPN and other blood cancers. With increased therapeutic targeting of diverse molecular, cellular and extra-cellular components of the marrow, these approaches can address the unmet need for improved objective and quantitative measures of disease modification in the context of clinical trials. This review focuses on the state-of-the-art in image analysis/AI of bone marrow tissue, with an emphasis on its potential to complement and inform future clinical studies and research in MPN.

摘要

骨髓增生性肿瘤(MPN)的诊断需要整合临床、形态学、遗传学和免疫表型发现。最近,我们对疾病起始和进展的细胞和分子机制的理解发生了转变。这伴随着高通量定量分子技术的广泛应用。相比之下,血液学家/血液病理学家对骨髓活检的显微镜解释仍然是主观和定性的。然而,组织图像分析和人工智能(AI)的进步有望改变血液病理学。骨髓图像分析的开创性研究有望深化我们对反应性样本和 MPN 亚型之间界限的理解,并更好地捕捉高危疾病的形态学相关性。它们还展示了在 MPN 和其他血液癌的当前和新型治疗药物评估方面的潜力。随着对骨髓中不同分子、细胞和细胞外成分的治疗靶向增加,这些方法可以满足在临床试验中改进疾病改善的客观和定量测量的未满足需求。本综述重点介绍了骨髓组织图像分析/AI 的最新技术,强调了其在补充和告知未来 MPN 临床研究和研究方面的潜力。

相似文献

1
Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?骨髓活检在 MPN 中的定量解读——在分子时代有何意义?
Br J Haematol. 2023 Nov;203(4):523-535. doi: 10.1111/bjh.19154. Epub 2023 Oct 19.
2
Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.基于人工智能的巨核细胞形态指纹识别:一种评估骨髓增殖性肿瘤患者疾病的新工具。
Blood Adv. 2020 Jul 28;4(14):3284-3294. doi: 10.1182/bloodadvances.2020002230.
3
Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry.骨髓活检报告的变异性影响骨髓增殖性肿瘤诊断的准确性:来自 ALLG MPN01 登记处的数据。
Pathology. 2024 Feb;56(1):75-80. doi: 10.1016/j.pathol.2023.09.012. Epub 2023 Nov 22.
4
Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.组织芯片技术适用于骨髓增殖性肿瘤的骨髓活检。
Histochem Cell Biol. 2017 Jan;147(1):75-82. doi: 10.1007/s00418-016-1476-x. Epub 2016 Aug 20.
5
Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.重塑骨髓微环境——靶向 MPN 中促炎贡献物的建议。
Front Immunol. 2020 Aug 31;11:2093. doi: 10.3389/fimmu.2020.02093. eCollection 2020.
6
[Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].[骨髓活检在骨髓增殖性肿瘤诊断中的应用]
Gac Med Mex. 2016 May-Jun;152(3):407-18.
7
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.纤维化的持续指数化(CIF):改善 MPN 患者的评估和分类。
Leukemia. 2023 Feb;37(2):348-358. doi: 10.1038/s41375-022-01773-0. Epub 2022 Dec 5.
8
[The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].[无法分类的骨髓增殖性肿瘤——形态学、细胞遗传学及临床特征]
Acta Med Croatica. 2011 Sep;65 Suppl 1:31-6.
9
[Myelodysplastic/myeloproliferative neoplasm: a histopathological review].骨髓增生异常/骨髓增殖性肿瘤:组织病理学综述
Rinsho Ketsueki. 2018;59(10):2084-2088. doi: 10.11406/rinketsu.59.2084.
10
Molecular Pathogenesis of Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分子发病机制
Curr Hematol Malig Rep. 2022 Dec;17(6):319-329. doi: 10.1007/s11899-022-00685-1. Epub 2022 Nov 7.

引用本文的文献

1
The utility of automated artificial intelligence-assisted digital cytomorphology for bone marrow analysis in diagnostic haemato-oncology.自动化人工智能辅助数字细胞形态学在诊断血液肿瘤学骨髓分析中的应用
Clin Transl Med. 2025 Jul;15(7):e70364. doi: 10.1002/ctm2.70364.
2
Reticulin-Free Quantitation of Bone Marrow Fibrosis in MPNs: Utility and Applications.骨髓增殖性肿瘤中无网硬蛋白定量评估骨髓纤维化:效用及应用
EJHaem. 2025 Feb 27;6(2):e70005. doi: 10.1002/jha2.70005. eCollection 2025 Apr.
3
Application of Pathomic Features for Differentiating Dysplastic Cells in Patients with Myelodysplastic Syndrome.

本文引用的文献

1
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.重新审视循环细胞外基质片段作为骨髓纤维化及相关肿瘤的疾病标志物
Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323.
2
Artificial Intelligence in Bone Marrow Histological Diagnostics: Potential Applications and Challenges.人工智能在骨髓组织学诊断中的应用:潜在的应用和挑战。
Pathobiology. 2024;91(1):8-17. doi: 10.1159/000529701. Epub 2023 Feb 15.
3
DECIDE-AI: a new reporting guideline and its relevance to artificial intelligence studies in radiology.
病理特征在鉴别骨髓增生异常综合征患者发育异常细胞中的应用
Bioengineering (Basel). 2024 Dec 5;11(12):1230. doi: 10.3390/bioengineering11121230.
4
Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.骨髓纤维化的定量分析突出了骨髓纤维化的异质性并增强了组织学评估:来自阿法锌pentraxin II期临床研究的见解。
Hemasphere. 2024 Jun 13;8(6):e105. doi: 10.1002/hem3.105. eCollection 2024 Jun.
DECIDE-AI:一种新的报告指南及其与放射学人工智能研究的相关性。
Clin Radiol. 2023 Feb;78(2):130-136. doi: 10.1016/j.crad.2022.09.131.
4
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.纤维化的持续指数化(CIF):改善 MPN 患者的评估和分类。
Leukemia. 2023 Feb;37(2):348-358. doi: 10.1038/s41375-022-01773-0. Epub 2022 Dec 5.
5
Genetic basis and molecular profiling in myeloproliferative neoplasms.骨髓增殖性肿瘤的遗传基础和分子谱分析。
Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578.
6
Multi-Scale Graphical Representation of Cell Environment.细胞环境的多尺度图形表示。
Annu Int Conf IEEE Eng Med Biol Soc. 2022 Jul;2022:3522-3525. doi: 10.1109/EMBC48229.2022.9871710.
7
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis.130例慢性三阴性血小板增多症患者的组织学和遗传学特征及随访
Haematologica. 2022 Nov 1;107(11):2725-2731. doi: 10.3324/haematol.2022.280917.
8
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类:整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
9
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版:髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
10
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.